Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells

Implications for adoptive immunotherapy of cancer

Mahadev Rao, Nachimuthu Chinnasamy, Julie A. Hong, Yuwei Zhang, Mary Zhang, Sichuan Xi, Fang Liu, Victor E. Marquez, Richard A. Morgan, David S. Schrump

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

Cancer-testis antigens (CTA), such as NY-ESO-1, MAGE-A1, and MAGE-A3, are immunogenic proteins encoded by genes, which are normally expressed only in male germ cells but are activated by ill-defined epigenetic mechanisms in human tumors, including lung cancers. Previously, we reported induction of these CTAs in cancer cells, but not normal cells, by DNA-demethylating agents and histone deacetylase inhibitors using clinically achievable exposure conditions. In the present study, we evaluated chromatin alterations associated with repression/activation of cancer-testis genes in lung cancer cells to further develop geneinduction regimens for cancer immunotherapy. Repression of NY-ESO-1, MAGE-A1, and MAGE-A3 coincided with DNA hypermethylation, recruitment, and binding of polycomb-group proteins, and histone heterochromatin modifications within the promoters of these genes. Derepression coincided with DNA demethylation, dissociation of polycomb proteins, and presence of euchromatin marks within the respective promoters. Short hairpin RNAs were used to inhibit several histone methyltransferases (KMT) and histone demethylases (KDM) that mediate histone methylation and repress gene expression. Knockdown of KMT6, KDM1, or KDM5B markedly enhanced deoxyazacytidine (DAC)-mediated activation of these cancer-testis genes in lung cancer cells. DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown. Following DAC-DZNep exposure, lung cancer cells were specifically recognized and lysed by allogeneic lymphocytes expressing recombinant T-cell receptors recognizing NY-ESO-1 and MAGE-A3. Combining DNA-demethylating agents with compounds, such as DZNep, that modulate histone lysine methylation may provide a novel epigenetic strategy to augment cancer-testis gene expression as an adjunct to adoptive cancer immunotherapy.

Original languageEnglish
Pages (from-to)4192-4204
Number of pages13
JournalCancer Research
Volume71
Issue number12
DOIs
Publication statusPublished - 15-06-2011

Fingerprint

Adoptive Immunotherapy
Testicular Neoplasms
Histones
Methylation
Lysine
Lung Neoplasms
Neoplasm Genes
Antigens
DNA
Neoplasms
Epigenomics
Histone Code
Histone Demethylases
Polycomb-Group Proteins
Euchromatin
Gene Expression
Histone Deacetylase Inhibitors
Heterochromatin
T-Cell Antigen Receptor
Germ Cells

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Rao, Mahadev ; Chinnasamy, Nachimuthu ; Hong, Julie A. ; Zhang, Yuwei ; Zhang, Mary ; Xi, Sichuan ; Liu, Fang ; Marquez, Victor E. ; Morgan, Richard A. ; Schrump, David S. / Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells : Implications for adoptive immunotherapy of cancer. In: Cancer Research. 2011 ; Vol. 71, No. 12. pp. 4192-4204.
@article{fc12b07be30a40ac8c59151b86c2dfaf,
title = "Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: Implications for adoptive immunotherapy of cancer",
abstract = "Cancer-testis antigens (CTA), such as NY-ESO-1, MAGE-A1, and MAGE-A3, are immunogenic proteins encoded by genes, which are normally expressed only in male germ cells but are activated by ill-defined epigenetic mechanisms in human tumors, including lung cancers. Previously, we reported induction of these CTAs in cancer cells, but not normal cells, by DNA-demethylating agents and histone deacetylase inhibitors using clinically achievable exposure conditions. In the present study, we evaluated chromatin alterations associated with repression/activation of cancer-testis genes in lung cancer cells to further develop geneinduction regimens for cancer immunotherapy. Repression of NY-ESO-1, MAGE-A1, and MAGE-A3 coincided with DNA hypermethylation, recruitment, and binding of polycomb-group proteins, and histone heterochromatin modifications within the promoters of these genes. Derepression coincided with DNA demethylation, dissociation of polycomb proteins, and presence of euchromatin marks within the respective promoters. Short hairpin RNAs were used to inhibit several histone methyltransferases (KMT) and histone demethylases (KDM) that mediate histone methylation and repress gene expression. Knockdown of KMT6, KDM1, or KDM5B markedly enhanced deoxyazacytidine (DAC)-mediated activation of these cancer-testis genes in lung cancer cells. DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown. Following DAC-DZNep exposure, lung cancer cells were specifically recognized and lysed by allogeneic lymphocytes expressing recombinant T-cell receptors recognizing NY-ESO-1 and MAGE-A3. Combining DNA-demethylating agents with compounds, such as DZNep, that modulate histone lysine methylation may provide a novel epigenetic strategy to augment cancer-testis gene expression as an adjunct to adoptive cancer immunotherapy.",
author = "Mahadev Rao and Nachimuthu Chinnasamy and Hong, {Julie A.} and Yuwei Zhang and Mary Zhang and Sichuan Xi and Fang Liu and Marquez, {Victor E.} and Morgan, {Richard A.} and Schrump, {David S.}",
year = "2011",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-10-2442",
language = "English",
volume = "71",
pages = "4192--4204",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells : Implications for adoptive immunotherapy of cancer. / Rao, Mahadev; Chinnasamy, Nachimuthu; Hong, Julie A.; Zhang, Yuwei; Zhang, Mary; Xi, Sichuan; Liu, Fang; Marquez, Victor E.; Morgan, Richard A.; Schrump, David S.

In: Cancer Research, Vol. 71, No. 12, 15.06.2011, p. 4192-4204.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells

T2 - Implications for adoptive immunotherapy of cancer

AU - Rao, Mahadev

AU - Chinnasamy, Nachimuthu

AU - Hong, Julie A.

AU - Zhang, Yuwei

AU - Zhang, Mary

AU - Xi, Sichuan

AU - Liu, Fang

AU - Marquez, Victor E.

AU - Morgan, Richard A.

AU - Schrump, David S.

PY - 2011/6/15

Y1 - 2011/6/15

N2 - Cancer-testis antigens (CTA), such as NY-ESO-1, MAGE-A1, and MAGE-A3, are immunogenic proteins encoded by genes, which are normally expressed only in male germ cells but are activated by ill-defined epigenetic mechanisms in human tumors, including lung cancers. Previously, we reported induction of these CTAs in cancer cells, but not normal cells, by DNA-demethylating agents and histone deacetylase inhibitors using clinically achievable exposure conditions. In the present study, we evaluated chromatin alterations associated with repression/activation of cancer-testis genes in lung cancer cells to further develop geneinduction regimens for cancer immunotherapy. Repression of NY-ESO-1, MAGE-A1, and MAGE-A3 coincided with DNA hypermethylation, recruitment, and binding of polycomb-group proteins, and histone heterochromatin modifications within the promoters of these genes. Derepression coincided with DNA demethylation, dissociation of polycomb proteins, and presence of euchromatin marks within the respective promoters. Short hairpin RNAs were used to inhibit several histone methyltransferases (KMT) and histone demethylases (KDM) that mediate histone methylation and repress gene expression. Knockdown of KMT6, KDM1, or KDM5B markedly enhanced deoxyazacytidine (DAC)-mediated activation of these cancer-testis genes in lung cancer cells. DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown. Following DAC-DZNep exposure, lung cancer cells were specifically recognized and lysed by allogeneic lymphocytes expressing recombinant T-cell receptors recognizing NY-ESO-1 and MAGE-A3. Combining DNA-demethylating agents with compounds, such as DZNep, that modulate histone lysine methylation may provide a novel epigenetic strategy to augment cancer-testis gene expression as an adjunct to adoptive cancer immunotherapy.

AB - Cancer-testis antigens (CTA), such as NY-ESO-1, MAGE-A1, and MAGE-A3, are immunogenic proteins encoded by genes, which are normally expressed only in male germ cells but are activated by ill-defined epigenetic mechanisms in human tumors, including lung cancers. Previously, we reported induction of these CTAs in cancer cells, but not normal cells, by DNA-demethylating agents and histone deacetylase inhibitors using clinically achievable exposure conditions. In the present study, we evaluated chromatin alterations associated with repression/activation of cancer-testis genes in lung cancer cells to further develop geneinduction regimens for cancer immunotherapy. Repression of NY-ESO-1, MAGE-A1, and MAGE-A3 coincided with DNA hypermethylation, recruitment, and binding of polycomb-group proteins, and histone heterochromatin modifications within the promoters of these genes. Derepression coincided with DNA demethylation, dissociation of polycomb proteins, and presence of euchromatin marks within the respective promoters. Short hairpin RNAs were used to inhibit several histone methyltransferases (KMT) and histone demethylases (KDM) that mediate histone methylation and repress gene expression. Knockdown of KMT6, KDM1, or KDM5B markedly enhanced deoxyazacytidine (DAC)-mediated activation of these cancer-testis genes in lung cancer cells. DZNep, a pharmacologic inhibitor of KMT6 expression, recapitulated the effects of KMT6 knockdown. Following DAC-DZNep exposure, lung cancer cells were specifically recognized and lysed by allogeneic lymphocytes expressing recombinant T-cell receptors recognizing NY-ESO-1 and MAGE-A3. Combining DNA-demethylating agents with compounds, such as DZNep, that modulate histone lysine methylation may provide a novel epigenetic strategy to augment cancer-testis gene expression as an adjunct to adoptive cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=79958822224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79958822224&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-2442

DO - 10.1158/0008-5472.CAN-10-2442

M3 - Article

VL - 71

SP - 4192

EP - 4204

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 12

ER -